529 / 1024
•
Multicenter study
•
Prospective
•
Inoperable T1/T2 NSCLC
•
N=60
•
Period: 2003-2005
•
SBRT
•
Dose: 45 Gy at 15 Gy/fx
•
Grade 3 toxicity: 21%
•
Local control 96%
•
OS: 65%
Baumann et al. Radiotherapy and Oncology 88 (2008) 359–367